Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report
Filed with HKEX · Stock code 512 · · 2 pages · English
The Current Corporate Communication of the Company has been published in English and Chinese languages and is available on the website of the Company at www.grandpharm.com and the HKEXnews (the “HKEXnews”) website at www.hkexnews.hk. (Note For the shareholders who have selected to receive the Company’s Corporate Communications (the “Corporate Communications”) 1) in printed version, enclosed is the
Grand Pharmaceutical Group Limited on 6ix
Earlier from Grand Pharmaceutical
- The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
- Voluntary announcement: the global innovation product of The Group STC3141 was approved to commence phase IIa clinical research in related to COVID-19 in Belgium
- China Grand Pharmaceutical and Healthcare: GP (HK)'s First-In-Class Drug STC3141 for Sepsis has been granted A 'Notice of Approval for Clinical Trial of Drugs' issued by the NMPA
- China Grand Pharmaceutical and Healthcare: GP (HK)'s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate Breaking Through the Blue Ocean of The Ophthalmic Market Segment
- Voluntary announcement: first patient dosed in the Phase 1B clinical trial for sepsis of the Group first-in-class drug STC3141
Later from Grand Pharmaceutical
- Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report
- Interim report 2026
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Proposed change of auditors
Follow Grand Pharmaceutical into a list and get an email when it puts out news.
Follow Grand Pharmaceutical